Filter
|
|
|
Frangula alnus
|
|
|
|
|
|
GSE99872
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies I
|
|
|
6
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
GSE99873
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies II
|
|
|
14
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
GSE99874
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies III
|
|
|
7
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
GSE100307
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies IV
|
|
|
7
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
GSE100308
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies V
|
|
|
7
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
GSE100309
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VI
|
|
|
7
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
GSE100310
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VII
|
|
|
7
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
GSE100438
|
Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies
|
|
|
55
|
|
|
Jeff Gildersleeve
|
Aug 25, 2017
|
GSE83087
|
Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins
|
|
|
168
|
|
|
Jeff Gildersleeve
|
Dec 13, 2016
|
GSE68403
|
Development of a glycan microarray based method for ABO blood typing
|
|
|
220
|
|
|
Jeff Gildersleeve
|
Apr 28, 2016
|
GSE68404
|
Determination of ABO blood type for prostate cancer patients
|
|
|
111
|
|
|
Jeff Gildersleeve
|
Apr 28, 2016
|
GSE68405
|
A Simple, Inexpensive Strategy for Predicting Potential Beneficial Clinical Responses on Prostate Cancer Vaccine Therapy
|
|
|
331
|
|
|
Jeff Gildersleeve
|
Apr 28, 2016
|
GSE50230
|
Post-vaccination serum anti-glycan IgG antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
|
|
|
28
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
GSE50231
|
Post-vaccination serum anti-glycan IgM antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
|
|
|
28
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
GSE50232
|
Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
|
|
|
28
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
GSE50233
|
Post-vaccination serum anti-glycan total Ig antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200)
|
|
|
28
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
GSE50235
|
Post-vaccination serum anti-glycan IgG antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
|
|
|
113
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
GSE50236
|
Baseline serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
|
|
|
113
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
GSE50237
|
Baseline serum anti-glycan IgM antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:50)
|
|
|
113
|
|
|
Christopher Campbell
|
Aug 26, 2015
|
GSE50239
|
Post-vaccination serum anti-glycan total Ig antibodies of 113 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine. (Dilution = 1:200)
|
|
|
113
|
|
|
Christopher Campbell
|
Aug 26, 2015
|